Boehringer Ingelheim snags second client for its China CMO operation

Just days after announcing its inaugural deal, Boehringer Ingelheim's contract manufacturing operation in China has picked up a second client. The German drugmaker last week said it has an agreement to manufacture a monoclonal antibody candidate for Shanghai-based biotech ZAI Lab. This deal comes shortly after Boehringer said it has won its first client with a deal to manufacture immuno-oncology drugs for Beijing-based BeiGene, once it completes construction of a €35 million ($44.9 million) plant it is building in Shanghai. The facility, which the company is using to do contract manufacturing in China, is slated to be operational in Q1 2017 and to have about 65 employees. Release (PDF) | More

Suggested Articles

As a key global ingredient supplier, problems in China can ripple worldwide as they have for Swiss CDMO Lonza.

What challenges continue to plague the pharmaceutical industry for almost a decade? Check out this remarkable innovation in glass science that may be the…

WuXi Biologics says its plant in Wuxi, China, has gotten the go-ahead from the FDA to make HIV drug Trogarzo for TaiMed Biologics.